COVID-19, the infectious disease caused by the SARS-CoV-2 virus, has been associated with an inflammatory and hypercoagulable state characterized by increases in levels of D-dimers, fibrin, fibrin degradation products, and fibrinogen. Observational studies suggest that elevations in levels of these markers translate into increased rates of mortality and thromboembolic events. These findings motivated the design and conduct of several randomized clinical trials aimed at evaluating the efficacy and safety of different antithrombotic regimens in patients with COVID-19.
Source: JAMA Online First